{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:38:11Z","timestamp":1793871491387,"version":"4.6.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Dalbavancin, approved in 2014 for Gram-positive acute bacterial skin and skin structure infections (ABSSSI), has pharmacokinetics enabling treatment with one or two doses. Dalbavancin might be useful in outpatient parenteral antibiotic therapy (OPAT) of deep-seated infections, otherwise requiring inpatient admission. We documented our experience with pragmatic dalbavancin use to assess its effectiveness for varied indications, on- and off-label, as primary or sequential consolidation therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients prescribed dalbavancin between 1 December 2021 and 1 October 2022 were screened for demographics of age, sex, Charlson comorbidity index (CCI), allergies, pathogens, doses of dalbavancin, other antibiotics administered and surgery. Where available, infection markers were recorded. The primary outcome was a cure at the end of treatment. Secondary outcomes  included any\u00a0adverse events and for those with\u00a0treatment failures, response to salvage antibiotics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-seven per cent of patients were cured. Cure rates by indication were 93% for ABSSSI, 100% for bacteraemia, 90% for acute osteomyelitis, 0% for chronic osteomyelitis, 75% for native joint septic arthritis and 33% for prosthetic joint infection. Most bone and joint infections that were\u00a0not cured did not have source control, and the goal of treatment was suppressive. Successful suppression rates were greater at 48% for chronic osteomyelitis and 66% for prosthetic joint infections. Adverse events occurred in 14 of 102 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This report adds to clinical experience with dalbavancin for off-label indications whilst further validating its role in ABSSSI. Dalbavancin as primary therapy in deep-seated infections merits investigation in formal clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-023-02152-2","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T10:04:31Z","timestamp":1704189871000},"page":"567-576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service"],"prefix":"10.1007","volume":"52","author":[{"given":"James C","family":"McSorley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshini","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Tonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vhairi","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"key":"2152_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1471-2334-14-92","volume":"14","author":"C Vazquez-Guillamet","year":"2014","unstructured":"Vazquez-Guillamet C, Kollef MH. Treatment of Gram-positive infections in critically ill patients. BMC Infect Dis. 2014;14:92. https:\/\/doi.org\/10.1186\/1471-2334-14-92. (PMID: 25431211; PMCID: PMC4289239).","journal-title":"BMC Infect Dis"},{"key":"2152_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","volume":"28","author":"SY Tong","year":"2015","unstructured":"Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28:603\u201361. https:\/\/doi.org\/10.1128\/CMR.00134-14. (PMID: 26016486; PMCID: PMC4451395).","journal-title":"Clin Microbiol Rev"},{"key":"2152_CR3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1302\/2058-5241.1.000017","volume":"1","author":"M Panteli","year":"2017","unstructured":"Panteli M, Giannoudis PV. Chronic osteomyelitis: what the surgeon needs to know. EFORT Open Rev. 2017;1:128\u201335. https:\/\/doi.org\/10.1302\/2058-5241.1.000017. (PMID: 28461939; PMCID: PMC5367612).","journal-title":"EFORT Open Rev"},{"key":"2152_CR4","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1128\/MMBR.00013-14","volume":"78","author":"D Lebeaux","year":"2014","unstructured":"Lebeaux D, Ghigo JM, Beloin C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol Mol Biol Rev. 2014;78:510\u201343. https:\/\/doi.org\/10.1128\/MMBR.00013-14. (PMID: 25184564; PMCID: PMC4187679).","journal-title":"Microbiol Mol Biol Rev"},{"key":"2152_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00134-016-4480-7","volume":"43","author":"C Beloin","year":"2017","unstructured":"Beloin C, Fern\u00e1ndez-Hidalgo N, Lebeaux D. Understanding biofilm formation in intravascular device-related infections. Intensive Care Med. 2017;43:443\u20136. https:\/\/doi.org\/10.1007\/s00134-016-4480-7. (Epub 2016 Aug 6 PMID: 27497588).","journal-title":"Intensive Care Med"},{"key":"2152_CR6","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1111\/jocs.14690","volume":"35","author":"C Radcliffe","year":"2020","unstructured":"Radcliffe C, Grant M. Over 870 days of successful antibiotic suppression therapy for VRE-infected left ventricular assist device. J Card Surg. 2020;35:1746\u20138. https:\/\/doi.org\/10.1111\/jocs.14690. (Epub 2020 Jun 19 PMID: 32557822).","journal-title":"J Card Surg"},{"key":"2152_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1086\/341417","volume":"35","author":"TT Yoshikawa","year":"2002","unstructured":"Yoshikawa TT, Cunha BA. Osteomyelitis in elderly patients. Clin Inf Dis. 2002;35:287\u201393. https:\/\/doi.org\/10.1086\/341417.","journal-title":"Clin Inf Dis"},{"key":"2152_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/cid\/cir842","volume":"54","author":"B Spellberg","year":"2012","unstructured":"Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis. 2012;54:393\u2013407. https:\/\/doi.org\/10.1093\/cid\/cir842.","journal-title":"Clin Infect Dis"},{"key":"2152_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004439.pub3","author":"LO Conterno","year":"2013","unstructured":"Conterno LO, Turchi MD. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev. 2013. https:\/\/doi.org\/10.1002\/14651858.CD004439.pub3. (PMID: 24014191).","journal-title":"Cochrane Database Syst Rev"},{"key":"2152_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/jac\/33.3.387","volume":"33","author":"JF Westphal","year":"1994","unstructured":"Westphal JF, Vetter D, Brogard JM. Hepatic side-effects of antibiotics. J Antimicrob Chemother. 1994;33:387\u2013401. https:\/\/doi.org\/10.1093\/jac\/33.3.387. (PMID: 8040106).","journal-title":"J Antimicrob Chemother"},{"key":"2152_CR11","doi-asserted-by":"publisher","first-page":"ii45","DOI":"10.1093\/jac\/dkg253","volume":"51","author":"G French","year":"2003","unstructured":"French G. Safety and tolerability of linezolid. J Antimicrob Chemother. 2003;51:ii45-53. https:\/\/doi.org\/10.1093\/jac\/dkg253. (PMID: 12730142).","journal-title":"J Antimicrob Chemother"},{"key":"2152_CR12","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/s0924-8579(98)00068-5","volume":"12","author":"K Christiansen","year":"1999","unstructured":"Christiansen K. Fusidic acid adverse drug reactions. Int J Antimicrob Agents. 1999;12:S3\u20139. https:\/\/doi.org\/10.1016\/s0924-8579(98)00068-5. (PMID: 10528781).","journal-title":"Int J Antimicrob Agents"},{"key":"2152_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/s0732-8893(99)00116-9","volume":"36","author":"SC Chang","year":"2000","unstructured":"Chang SC, Hsieh SM, Chen ML, Sheng WH, Chen YC. Oral fusidic acid fails to eradicate methicillin-resistant Staphylococcus aureus colonization and results in emergence of fusidic acid-resistant strains. Diagn Microbiol Infect Dis. 2000;36:131\u20136. https:\/\/doi.org\/10.1016\/s0732-8893(99)00116-9. (PMID: 10705056).","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2152_CR14","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1093\/jac\/47.5.647","volume":"47","author":"AJ O'Neill","year":"2001","unstructured":"O\u2019Neill AJ, Cove JH, Chopra I. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. J Antimicrob Chemother. 2001;47:647\u201350. https:\/\/doi.org\/10.1093\/jac\/47.5.647. (PMID: 11328777).","journal-title":"J Antimicrob Chemother"},{"key":"2152_CR15","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/cid\/ciw665","volume":"63","author":"R Pushkin","year":"2016","unstructured":"Pushkin R, et al. A randomized study evaluating oral fusidic acid (CEM-102) in combination with oral rifampin compared with standard-of-care antibiotics for treatment of prosthetic joint infections: a newly identified drug\u2013drug interaction. Clin Infect Dis. 2016;63:1599\u2013604.","journal-title":"Clin Infect Dis"},{"key":"2152_CR16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1399-6576.2005.00685.x","volume":"49","author":"G Chanques","year":"2005","unstructured":"Chanques G, Girard C, Pinzani V. Fatal pristinamycin-induced toxic epidermal necrolysis (Lyell\u2019s syndrome): difficulties in attributing causal association in the polymedicated intensive care unit patient. Acta Anaesthesiol Scand. 2005;49:721\u20132.","journal-title":"Acta Anaesthesiol Scand"},{"key":"2152_CR17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1086\/382084","volume":"38","author":"DN Gerding","year":"2004","unstructured":"Gerding DN. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis. 2004;38:646\u20138. https:\/\/doi.org\/10.1086\/382084. (Epub 2004 Feb 11 PMID: 14986247).","journal-title":"Clin Infect Dis"},{"key":"2152_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/14656566.2018.1442826","volume":"19","author":"A Khan","year":"2018","unstructured":"Khan A, Wilson B, Gould IM. Current and future treatment options for community-associated MRSA infection. Expert Opin Pharmacother. 2018;19:457\u201370. https:\/\/doi.org\/10.1080\/14656566.2018.1442826. (Epub 2018 Feb 26 PMID: 29480032).","journal-title":"Expert Opin Pharmacother"},{"key":"2152_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4103\/cjrm.cjrm_67_20","volume":"26","author":"L Kelly","year":"2021","unstructured":"Kelly L, Schreiber YS, Hopko J, Kirkwood T, Kattini R, Poirier D, Madden S. Fluoroquinolone use in a rural practice. Can J Rural Med. 2021;26:14\u20138. https:\/\/doi.org\/10.4103\/cjrm.cjrm_67_20. (PMID: 33380601).","journal-title":"Can J Rural Med"},{"key":"2152_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2022.102403","volume":"49","author":"A Kantele","year":"2022","unstructured":"Kantele A, Mero S, L\u00e4\u00e4veri T. Doxycycline as an antimalarial: Impact on travellers\u2019 diarrhoea and doxycycline resistance among various stool bacteria\u2014prospective study and literature review. Travel Med Infect Dis. 2022;49: 102403. https:\/\/doi.org\/10.1016\/j.tmaid.2022.102403. (Epub 2022 Jul 21 PMID: 35872253).","journal-title":"Travel Med Infect Dis"},{"key":"2152_CR21","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3390\/antibiotics9120884","volume":"9","author":"P Shinu","year":"2020","unstructured":"Shinu P, Bareja R, Nair AB, Mishra V, Hussain S, Venugopala KN, Sreeharsha N, Attimarad M, Rasool ST. Monitoring of non-\u03b2-lactam antibiotic resistance-associated genes in ESBL producing Enterobacterales isolates. Antibiotics (Basel). 2020;9:884. https:\/\/doi.org\/10.3390\/antibiotics9120884. (PMID: 33317078; PMCID: PMC7764327).","journal-title":"Antibiotics (Basel)"},{"key":"2152_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jgar.2020.10.020","volume":"23","author":"IA Critchley","year":"2020","unstructured":"Critchley IA, Cotroneo N, Pucci MJ, Jain A, Mendes RE. Resistance among urinary tract pathogens collected in Europe during 2018. J Glob Antimicrob Resist. 2020;23:439\u201344. https:\/\/doi.org\/10.1016\/j.jgar.2020.10.020. (Epub 2020 Nov 16 PMID: 33212286).","journal-title":"J Glob Antimicrob Resist"},{"key":"2152_CR23","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1128\/AAC.01341-06","volume":"51","author":"V Ayer","year":"2007","unstructured":"Ayer V, Tewodros W, Manoharan A, Skariah S, Luo F, Bessen DE. Tetracycline resistance in group a streptococcus: emergence on a global scale and influence on multiple-drug resistance. Antimicrob Agents Chemother. 2007;51:1865\u20138. https:\/\/doi.org\/10.1128\/AAC.01341-06. (Epub 2007 Feb 16. PMID: 17307980; PMCID: PMC1855555).","journal-title":"Antimicrob Agents Chemother"},{"key":"2152_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv133.1094","author":"SJ Eells","year":"2015","unstructured":"Eells SJ, Geffen DB, Nguyen MH, Jung J, Macias-Gil R, May LS, Miller LG. Examining the relationship between adherence to oral antibiotics and post-discharge clinical outcomes among patients hospitalized with Staphylococcus aureus skin infections. Open Forum Inf Dis. 2015. https:\/\/doi.org\/10.1093\/ofid\/ofv133.1094.","journal-title":"Open Forum Inf Dis"},{"key":"2152_CR25","doi-asserted-by":"publisher","first-page":"E167","DOI":"10.1017\/ash.2022.302","volume":"2","author":"D Theodore","year":"2022","unstructured":"Theodore D, Furuya E, Austin E, Greendyke W. Outcomes among patients with Staphylococcus aureus bacteremia enrolled in a postdischarge outpatient parenteral antibiotic therapy program at an academic medical center. Antimicrob Stewardship Healthc Epidemiol. 2022;2:E167. https:\/\/doi.org\/10.1017\/ash.2022.302.","journal-title":"Antimicrob Stewardship Healthc Epidemiol"},{"key":"2152_CR26","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3390\/antibiotics3040572","volume":"3","author":"E Binda","year":"2014","unstructured":"Binda E, Marinelli F, Marcone GL. Old and new glycopeptide antibiotics: action and resistance. Antibiotics. 2014;3:572\u201394. https:\/\/doi.org\/10.3390\/antibiotics3040572.","journal-title":"Antibiotics"},{"key":"2152_CR27","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1093\/jac\/dky235","volume":"73","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015\u201316. J Antimicrob Chemother. 2018;73:2748\u201356. https:\/\/doi.org\/10.1093\/jac\/dky235.","journal-title":"J Antimicrob Chemother"},{"key":"2152_CR28","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1179\/joc.2005.17.6.593","volume":"17","author":"RN Jones","year":"2005","unstructured":"Jones RN, Fritsche TR, Sader HS, Goldstein BP. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J Chemother. 2005;17:593\u2013600. https:\/\/doi.org\/10.1179\/joc.2005.17.6.593. (PMID: 16433188).","journal-title":"J Chemother"},{"key":"2152_CR29","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2147\/TCRM.S86330","volume":"12","author":"K Leuthner","year":"2016","unstructured":"Leuthner K, Buechler K, Kogan D, Saguros A, Lee S. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Ther Clin Risk Manage. 2016;12:931\u201340.","journal-title":"Ther Clin Risk Manage"},{"key":"2152_CR30","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1128\/AAC.01264-06","volume":"51","author":"D Andes","year":"2007","unstructured":"Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother. 2007;51:1633\u201342.","journal-title":"Antimicrob Agents Chemother"},{"key":"2152_CR31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.cmi.2019.12.023","volume":"26","author":"NE Holmes","year":"2020","unstructured":"Holmes NE. Using AUC\/MIC to guide vancomycin dosing: ready for prime time? Clin Microbiol Infect. 2020;26:406\u20138. https:\/\/doi.org\/10.1016\/j.cmi.2019.12.023. (Epub 2020 Jan 9 PMID: 31927116).","journal-title":"Clin Microbiol Infect"},{"key":"2152_CR32","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fmicb.2020.00553","volume":"11","author":"M \u017diemyt\u0117","year":"2020","unstructured":"\u017diemyt\u0117 M, Rodr\u00edguez-D\u00edaz JC, Ventero MP, Mira A, Ferrer MD. Effect of dalbavancin on staphylococcal biofilms when administered alone or in combination with biofilm-detaching compounds. Front Microbiol. 2020;11:553. https:\/\/doi.org\/10.3389\/fmicb.2020.00553. (PMID: 32362877; PMCID: PMC7180179).","journal-title":"Front Microbiol"},{"key":"2152_CR33","doi-asserted-by":"publisher","first-page":"e01090","DOI":"10.1128\/AAC.01090-17","volume":"61","author":"SE Hobdey","year":"2017","unstructured":"Hobdey SE, Katahira EJ, Dockstader P, Davidson SM, Bond L, Bolz DD, Bryant AE, Stevens DL. Subinhibitory dalbavancin attenuates exotoxin production from methicillin-sensitive and methicillin-resistant Staphylococcus aureus in vitro. Antimicrob Agents Chemother. 2017;61:e01090-e1117. https:\/\/doi.org\/10.1128\/AAC.01090-17. (PMID: 28874375; PMCID: PMC5655096).","journal-title":"Antimicrob Agents Chemother"},{"key":"2152_CR34","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1093\/jac\/dkz562","volume":"75","author":"KM Hines","year":"2020","unstructured":"Hines KM, Shen T, Ashford NK, Waalkes A, Penewit K, Holmes EA, McLean K, Salipante SJ, Werth BJ, Xu L. Occurrence of cross-resistance and \u03b2-lactam seesaw effect in glycopeptide-, lipopeptide- and lipoglycopeptide-resistant MRSA correlates with membrane phosphatidylglycerol levels. J Antimicrob Chemother. 2020;75:1182\u20136. https:\/\/doi.org\/10.1093\/jac\/dkz562. (PMID: 32016379; PMCID: PMC7869793).","journal-title":"J Antimicrob Chemother"},{"key":"2152_CR35","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1128\/AAC.04550-14","volume":"59","author":"MW Dunne","year":"2015","unstructured":"Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59:1849\u201355. https:\/\/doi.org\/10.1128\/AAC.04550-14. (Epub 2015 Jan 5. PMID: 25561338; PMCID: PMC4356775).","journal-title":"Antimicrob Agents Chemother."},{"key":"2152_CR36","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/jac\/dkm263","volume":"60","author":"DP Nicolau","year":"2007","unstructured":"Nicolau DP, Sun HK, Seltzer E, Buckwalter M, Dowell JA. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother. 2007;60:681\u20134. https:\/\/doi.org\/10.1093\/jac\/dkm263. (Epub 2007 Jul 12 PMID: 17631507).","journal-title":"J Antimicrob Chemother"},{"key":"2152_CR37","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1310\/hpj4909-851","volume":"49","author":"DJ Cada","year":"2014","unstructured":"Cada DJ, Ingram K, Baker DE. Dalbavancin. Hosp Pharm. 2014;49:851\u201361. https:\/\/doi.org\/10.1310\/hpj4909-851. (PMID: 25477617; PMCID: PMC4252189).","journal-title":"Hosp Pharm"},{"key":"2152_CR38","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3390\/antibiotics9120865","volume":"9","author":"D Bongiorno","year":"2020","unstructured":"Bongiorno D, Lazzaro LM, Stefani S, Campanile F. In vitro activity of dalbavancin against refractory multidrug-resistant (MDR) Staphylococcus aureus isolates. Antibiotics (Basel). 2020;9:865. https:\/\/doi.org\/10.3390\/antibiotics9120865. (PMID: 33287376; PMCID: PMC7761838).","journal-title":"Antibiotics (Basel)"},{"key":"2152_CR39","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2147\/TCRM.S271445","volume":"17","author":"O Simonetti","year":"2021","unstructured":"Simonetti O, Rizzetto G, Molinelli E, Cirioni O, Offidani A. Review: a safety profile of dalbavancin for on- and off-label utilization. Ther Clin Risk Manag. 2021;17:223\u201332. https:\/\/doi.org\/10.2147\/TCRM.S271445. (PMID: 33790563; PMCID: PMC7997409).","journal-title":"Ther Clin Risk Manag"},{"key":"2152_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy331","author":"U Rappo","year":"2018","unstructured":"Rappo U, Puttagunta S, Shevchenko V, Shevchenko A, Jandourek A, Gonzalez PL, Suen A, Mas Casullo V, Melnick D, Miceli R, Kovacevic M, De Bock G, Dunne MW. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis. 2018. https:\/\/doi.org\/10.1093\/ofid\/ofy331. (PMID: 30648126; PMCID: PMC6326511).","journal-title":"Open Forum Infect Dis"},{"key":"2152_CR41","doi-asserted-by":"publisher","unstructured":"Tobudic S, Forstner C, Burgmann H, Lagler H, Steininger C, Traby L, Vossen MG, Winkler S, Thalhammer F. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection. Infection. 2019;47:1013\u201320. https:\/\/doi.org\/10.1007\/s15010-019-01354-x. Epub 2019 Sep 13. Erratum in: Infection. 2019 Nov 18; PMID: 31520397.","DOI":"10.1007\/s15010-019-01354-x"},{"key":"2152_CR42","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/cid\/ciy279","volume":"67","author":"S Tobudic","year":"2018","unstructured":"Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, Vossen MG, Winkler S, Thalhammer F. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna. Clin Inf Dis. 2018;67:795\u20138. https:\/\/doi.org\/10.1093\/cid\/ciy279.","journal-title":"Clin Inf Dis"},{"key":"2152_CR43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","volume":"51","author":"E Bouza","year":"2018","unstructured":"Bouza E, Valerio M, Soriano A, Morata L, Carus EG, Rodr\u00edguez-Gonz\u00e1lez C, Hidalgo-Tenorio MC, Plata A, Mu\u00f1oz P, Vena A, DALBUSE Study Group (Dalbavancina: Estudio de suusoclinicoenEspa\u00f1a). Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018;51:571\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.11.008. (Epub 2017 Nov 24 PMID: 29180276).","journal-title":"Int J Antimicrob Agents."},{"key":"2152_CR44","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","volume":"8","author":"JT Bork","year":"2019","unstructured":"Bork JT, Heil EL, Berry S, Lopes E, Dav\u00e9 R, Gilliam BL, Amoroso A. Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections. Infect Dis Ther. 2019;8:171\u201384. https:\/\/doi.org\/10.1007\/s40121-019-0247-0. (Epub 2019 May 3. PMID: 31054088; PMCID: PMC6522607).","journal-title":"Infect Dis Ther."},{"key":"2152_CR45","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40261-021-01028-3","volume":"41","author":"M Poliseno","year":"2021","unstructured":"Poliseno M, Bavaro DF, Brindicci G, et al. Dalbavancin efficacy and impact on hospital length-of-stay and treatment costs in different gram-positive bacterial infections. Clin Drug Investig. 2021;41:437\u201348. https:\/\/doi.org\/10.1007\/s40261-021-01028-3.","journal-title":"Clin Drug Investig"},{"key":"2152_CR46","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","volume":"81","author":"S Wunsch","year":"2019","unstructured":"Wunsch S, Krause R, Valentin T, Prattes J, Janata O, Lenger A, Bellmann-Weiler R, Weiss G, Zollner-Schwetz I. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections. Int J Infect Dis. 2019;81:210\u20134. https:\/\/doi.org\/10.1016\/j.ijid.2019.02.013. (Epub 2019 Feb 19 PMID: 30794940).","journal-title":"Int J Infect Dis"},{"key":"2152_CR47","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s15010-020-01526-0","volume":"49","author":"F Hitzenbichler","year":"2021","unstructured":"Hitzenbichler F, Mohr A, Camboni D, et al. Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source\u2014a series of four cases. Infection. 2021;49:181\u20136. https:\/\/doi.org\/10.1007\/s15010-020-01526-0.","journal-title":"Infection"},{"key":"2152_CR48","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.2147\/DDDT.S313756","volume":"15","author":"M Gatti","year":"2021","unstructured":"Gatti M, Andreoni M, Pea F, Viale P. Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: a careful appraisal beyond approved indications focusing on unmet clinical needs. Drug Des Dev Ther. 2021;15:3349\u201378. https:\/\/doi.org\/10.2147\/DDDT.S313756.","journal-title":"Drug Des Dev Ther"},{"key":"2152_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac335","author":"KC Molina","year":"2022","unstructured":"Molina KC, Lunowa C, Lebin M, Nunez AS, Azimi SF, Krsak M, Mueller SW, Miller MA. Comparison of sequential dalbavancin with standard-of-care treatment for Staphylococcus aureus bloodstream infections. Open Forum Inf Dis. 2022. https:\/\/doi.org\/10.1093\/ofid\/ofac335.","journal-title":"Open Forum Inf Dis"},{"key":"2152_CR50","unstructured":"Joint Formulary Committee. British National Formulary. [84] ed. BMJ Group and Pharmaceutical Press, London; 2022."},{"key":"2152_CR51","doi-asserted-by":"publisher","unstructured":"Piorkowska M, Al-Raweshidy Z, Yeong K. Improving peripherally inserted central catheter (PICC) care on a trauma and orthopaedics ward. BMJ Qual Improv Rep. 2013;2: u464.w354. https:\/\/doi.org\/10.1136\/bmjquality. (u464.w354. PMID: 26734200; PMCID: PMC4652731).","DOI":"10.1136\/bmjquality"},{"key":"2152_CR52","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/cid\/ciac341","volume":"75","author":"R Zhang","year":"2022","unstructured":"Zhang R, Polenakovik H, Barreras Beltran IA, Waalkes A, Salipante SJ, Xu L, Werth BJ. Emergence of dalbavancin, vancomycin, and daptomycin nonsusceptible Staphylococcus aureus in a patient treated with dalbavancin: case report and isolate characterization. Clin Infect Dis. 2022;75:1641\u20134. https:\/\/doi.org\/10.1093\/cid\/ciac341. (PMID: 35510938).","journal-title":"Clin Infect Dis"},{"key":"2152_CR53","doi-asserted-by":"publisher","first-page":"910.e1","DOI":"10.1016\/j.cmi.2020.08.025","volume":"27","author":"BJ Werth","year":"2021","unstructured":"Werth BJ, Ashford NK, Penewit K, Waalkes A, Holmes EA, Ross DH, Shen T, Hines KM, Salipante SJ, Xu L. Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2021;27:910.e1-910.e8. https:\/\/doi.org\/10.1016\/j.cmi.2020.08.025. (Epub 2020 Aug 28. PMID: 32866650; PMCID: PMC7914275).","journal-title":"Clin Microbiol Infect"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02152-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-023-02152-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02152-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T05:59:12Z","timestamp":1710914352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-023-02152-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2152"],"URL":"https:\/\/doi.org\/10.1007\/s15010-023-02152-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3125495\/v1","asserted-by":"object"}]},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"29 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Patient-identifiable information was kept to a necessary minimum and anonymised to comply with NHS Scotland Caldicott principles for information governance and secure approval from the health board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}